Suppr超能文献

锝-99m甲氧基异丁基异腈乳腺闪烁显像在临床实践中的应用:对患者临床管理的影响

[Scintimammography with 99mTC-MIBI in the clinical practice: repercussion on the clinical management of the patient].

作者信息

Prats E, Razola P, Sainz J M, Tardín L, Andrés A, Abós M D, García F, Fernández J, Villavieja L, Banzo J

机构信息

Servicio de Medicina Nuclear, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

出版信息

Rev Esp Med Nucl. 2007 May-Jun;26(3):153-9.

Abstract

OBJECTIVE

Establish the usefulness of scintimammography (SM) in day-to-day clinical practice.

MATERIAL AND METHODS

We have evaluated 308 SM consecutively performed in our Department. The diagnosis was established by way of biopsy or clinical and mammography follow-up (minimum 18 months). In all cases we evaluated the kind of lesions (palpable or non-palpable) and their degree of suspicion of malignancy in the mammography (BIRADS). We determined the number of fine-needle aspiration cytology (FNAC) or biopsies performed in dependence of kind of lesions, mammography and SM results.

RESULTS

Final diagnosis was cancer in 18 % of the patients, and 71 % of the lesions were non palpable. Negative predictive value (NPV) of SM was 96 %. Pathological diagnosis was performed in 100 % of lesions with SM+ and 16 % of lesions with SM-. According to the kind of lesion, FNAC and/or biopsy was performed in 62 % of palpable lesions and in 20 % of non-palpable lesions; and according to the mammography in 21 % of lesions BIRADS I-II, 14 % in BIRADS III, 70 % in BIRADS IV and 100 % in BIRADS V. The number of FNAC and/or biopsies performed is significantly higher in all cases when SM is positive (p > 0,001), excepting in BIRADS V lesions.

CONCLUSIONS

In day-to-day clinical practice SM is generally performed in low prevalence of breast cancer population, in the evaluation of non-palpable lesions with a low suspicion of malignancy. SM has a high NPV, increase the diagnostic accuracy of the mammography and has repercussion on patient management, except in BIRADS V lesions.

摘要

目的

确立乳腺闪烁造影(SM)在日常临床实践中的实用性。

材料与方法

我们对本科室连续进行的308例乳腺闪烁造影进行了评估。通过活检或临床及乳腺X线摄影随访(至少18个月)来确立诊断。在所有病例中,我们评估了病变类型(可触及或不可触及)及其在乳腺X线摄影中(乳腺影像报告和数据系统,BIRADS)的恶性可疑程度。我们根据病变类型、乳腺X线摄影和乳腺闪烁造影结果确定了细针穿刺抽吸细胞学检查(FNAC)或活检的数量。

结果

18%的患者最终诊断为癌症,71%的病变不可触及。乳腺闪烁造影的阴性预测值(NPV)为96%。对所有乳腺闪烁造影阳性的病变均进行了病理诊断,而乳腺闪烁造影阴性的病变中这一比例为16%。根据病变类型,62%的可触及病变和20%的不可触及病变进行了FNAC和/或活检;根据乳腺X线摄影结果,乳腺影像报告和数据系统I-II类病变中有21%进行了FNAC和/或活检,III类病变中为14%,IV类病变中为70%,V类病变中为100%。除了乳腺影像报告和数据系统V类病变外,当乳腺闪烁造影呈阳性时,所有病例中进行FNAC和/或活检的数量均显著更高(p>0.001)。

结论

在日常临床实践中,乳腺闪烁造影通常在乳腺癌患病率较低的人群中进行,用于评估恶性可疑程度较低的不可触及病变。乳腺闪烁造影具有较高的阴性预测值,可提高乳腺X线摄影的诊断准确性,并对患者管理产生影响,但乳腺影像报告和数据系统V类病变除外。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验